This collaboration between Eli Lilly and a Top VC fund can redefine how Corporate VC (CVC) fuels innovation – not just in ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

However, #EliLilly did the unimaginable with a $500M investment into a new fund called 'Biotech Ecosystem Venture Fund' to be co-managed with Andreessen Horowitz. This is pushing the boundaries ...

Venture capital firm Andreessen Horowitz will be pulling back its operations in the UK in response to US President Donald Trump’s “strong policy momentum” on crypto. In a Jan. 24 X post ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from competitor Novo Nordisk (NYSE:NVO) regarding their new weight ...

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Eli Lilly (NYSE:LLY). While profit isn ...

(Bloomberg) -- Andreessen Horowitz will close down its UK office a little over a year after it opened, as it plans to focus on its home market under the crypto-friendly stance of US President ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Shares of pharmaceutical giant Eli Lilly have been falling in recent months. The company updated its guidance last week, and investors weren't impressed. It could be a tough year for Eli Lilly ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...